Getein β2-MG Fast Test Kit is used as an aid in the detection and evaluation of glomerular filtration rate, renal transplantation and renal function.
β2-MG Fast Test Kit
(Immunofluorescence Assay)
β2-MG Fast Test Kit (Immunofluorescence Assay) is intended for in vitro quantitative determination of beta 2-microglobulin(β2-MG) in serum, plasma or whole blood. Measurement ofβ2-MG is useful for the detection and evaluation of glomerular filtration rate, renal transplantation and renal function.
About β2-MG
β2-MG is an 11.8 kDa protein, which forms one of the chains of the major histocompatibility complex (MHC) class I molecule normally present on the surface of every nucleated cell in the human body. Ninety percent ofβ2-MG is eliminated via glomerular filtration and almost completely reabsorbed by the proximal tubule.β2-MG is present in small amounts in serum, CSF, and urine of normal people, and to a much greater degree in the urine and plasma of patients with tubular proteinemia, renal failure, or kidney transplants.
Contents
1. For Getein1100
Package specifications: 25 tests/box, 10 tests/box
1) β2-MGtest card in a sealed pouch with desiccant
2) Capillary pipet
3) Sample diluent
4) User manual: 1 piece/box
5) SD/RFID card: 1 piece/box
2. For Getein1600
Package specifications: 2×24 tests/kit, 2×48 tests/kit
1) Sealed cartridge with 24/48 Geteinβ2-MGtest cards
2) User manual: 1 piece/box
Materials required for Getein1600:
1) Sample diluent: 1 bottle/box
2) Box with pipette tips: 1 piece/box
3) Mixing plate: 1 piece/box
Note: Do not mix or interchange different batches of kits.
Specifications
Test Item |
Sample |
Method |
Storage Condition |
β2-MG |
S/P/WB |
Immunofluorescence Assay |
4-30℃ |
Detection Range |
Test Time |
Cut-off Value |
Shelf Life |
0.5~20.0 mg/L |
3 min |
0.8~3.0 mg/L |
24 months |
Applicable Device
Getein1100 Immunofluorescence Quantitative Analyzer
Getein1600 Immunofluorescence Quantitative Analyzer
Clinical Application
1. As an aid in the evaluation of the kidney disease.
2. Assessing the hypertension and kidney injury caused by diabetic nephropathy (DN).
3. The evaluation for prognosis and therapeutic effect of malignancies.
4. Posttransplantation lymphoproliferative disease (PTLD).
5. Glomerular filtration function.
6. Dynamic observation and diagnosis of the kidney transplant rejection.
7. Multiple myeloma.